The efficacy and safety of Erenumab in patients with chronic and episodic migraine

What is it about?

Migraine is a common neurological condition that can greatly affect daily life, work, and overall well-being. Many people use preventive medications to reduce migraine attacks, but traditional treatments may not work well for everyone and can cause unwanted side effects that make patients stop taking them. In this study, we analyzed data from 20 clinical trials involving more than 5,000 patients to evaluate how well Erenumab works for preventing migraines. Erenumab is a newer treatment that targets a specific pathway involved in migraine attacks. We found that Erenumab reduced the number of migraine days per month, lowered the need for migraine medications, and improved patients’ quality of life compared with placebo treatment. The treatment appeared to work especially well in people who had not responded to previous preventive therapies. We also found that both chronic and episodic migraine patients benefited from the treatment. Overall, Erenumab was generally safe, with constipation being the main side effect reported more often than with the placebo. These findings support the use of Erenumab as an effective preventive treatment option for people living with migraine, particularly for those who have not benefited from other therapies.

Featured Image

Photo by Vitaly Gariev on Unsplash

Photo by Vitaly Gariev on Unsplash

Why is it important?

This study provides one of the most comprehensive and up-to-date analyses of Erenumab for migraine prevention, including evidence from 20 randomized clinical trials and more than 5,000 patients. Unlike many previous studies, we performed detailed subgroup analyses to better understand which patients may benefit the most from treatment. Our findings showed that Erenumab may be especially helpful for patients who previously failed other preventive migraine treatments, a group that is often difficult to manage in clinical practice. We also compared different migraine types and treatment doses to provide more practical information for healthcare providers and patients. Migraine remains a major cause of disability worldwide, and there is a growing need for treatments that are both effective and well tolerated. By showing that Erenumab can reduce migraine frequency and improve quality of life with relatively few side effects, our work may help support more personalized and evidence-based treatment decisions for people living with migraine.